Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders.
暂无分享,去创建一个
M. Garcia-Parajo | F. Sanz | J. Corchero | S. Schwartz | A. Villaverde | Y. Fernández | I. Abasolo | M. Royo | M. Giannotti | Fernanda Andrade | M. Oliva | N. García-Aranda | Marta Melgarejo | Daniel Pulido | Yolanda Fernández
[1] Ignacio Insua,et al. Polyion complex (PIC) particles: Preparation and biomedical applications , 2016, European polymer journal.
[2] J. Veciana,et al. α‐Galactosidase‐A Loaded‐Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration , 2016, Advanced healthcare materials.
[3] S. Schwartz,et al. Multifunctionalized polyurethane-polyurea nanoparticles: hydrophobically driven self-stratification at the o/w interface modulates encapsulation stability. , 2015, Journal of materials chemistry. B.
[4] D. Lockhart,et al. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase , 2015, PloS one.
[5] C. Remuñán-López,et al. Hybrid nanosystems based on natural polymers as protein carriers for respiratory delivery: Stability and toxicological evaluation. , 2015, Carbohydrate polymers.
[6] J. Esko,et al. GNeosomes: Highly Lysosomotropic Nanoassemblies for Lysosomal Delivery. , 2015, ACS nano.
[7] Yoram Tekoah,et al. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease. , 2015, Molecular genetics and metabolism.
[8] Surajit Ghosh,et al. Novel lysosome targeted molecular transporter built on a guanidinium-poly-(propylene imine) hybrid dendron for efficient delivery of doxorubicin into cancer cells. , 2015, Chemical communications.
[9] Ahmed Jalal Khan Chowdhury,et al. Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: A review , 2014, Journal of food and drug analysis.
[10] Zhen Gu,et al. Stimuli-responsive nanomaterials for therapeutic protein delivery. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[11] K. Raghu,et al. A lysosome-targeted drug delivery system based on sorbitol backbone towards efficient cancer therapy. , 2014, Organic & biomolecular chemistry.
[12] C. Arús,et al. Ex vivo assessment of polyol coated-iron oxide nanoparticles for MRI diagnosis applications: toxicological and MRI contrast enhancement effects , 2014, Journal of Nanoparticle Research.
[13] V. Rotello,et al. Direct delivery of functional proteins and enzymes to the cytosol using nanoparticle-stabilized nanocapsules. , 2013, ACS nano.
[14] T. Kirkegaard. Emerging therapies and therapeutic concepts for lysosomal storage diseases , 2013 .
[15] Eleonore Fröhlich,et al. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles , 2012, International journal of nanomedicine.
[16] V. Préat,et al. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.
[17] A. Hajitou,et al. Clathrin-mediated Endocytosis and Subsequent Endo-Lysosomal Trafficking of Adeno-associated Virus/Phage* , 2012, The Journal of Biological Chemistry.
[18] Ruth Duncan,et al. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. , 2012, Molecular pharmaceutics.
[19] XinRan Li,et al. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity. , 2012, Bioconjugate chemistry.
[20] Carlos A. Muniesa,et al. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[21] V. Torchilin,et al. Screening and optimization of ligand conjugates for lysosomal targeting. , 2011, Bioconjugate chemistry.
[22] E. Vázquez,et al. Integrated approach to produce a recombinant, his‐tagged human α‐galactosidase a in mammalian cells , 2011, Biotechnology progress.
[23] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[24] J. Kamps,et al. Targeted siRNA delivery to diseased microvascular endothelial cells—Cellular and molecular concepts , 2011, IUBMB life.
[25] M. Garcia-Parajo,et al. pH-responsive polysaccharide-based polyelectrolyte complexes as nanocarriers for lysosomal delivery of therapeutic proteins. , 2011, Biomacromolecules.
[26] Xiaoyuan Chen,et al. Integrin Targeted Delivery of Chemotherapeutics , 2011, Theranostics.
[27] F. Kiessling,et al. Integrin Targeted Delivery of Radiotherapeutics , 2011, Theranostics.
[28] Silvia Muro,et al. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[29] B. Evrard,et al. Development of pH-responsive nanocarriers using trimethylchitosans and methacrylic acid copolymer for siRNA delivery. , 2010, Biomaterials.
[30] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[31] W. Hennink,et al. Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. , 2009, Biomaterials.
[32] V. Mourya,et al. Trimethyl chitosan and its applications in drug delivery , 2009, Journal of materials science. Materials in medicine.
[33] W. Hennink,et al. Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. , 2008, Biomaterials.
[34] Samir Mitragotri,et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] D. Bundle,et al. A novel linker methodology for the synthesis of tailored conjugate vaccines composed of complex carbohydrate antigens and specific TH-cell peptide epitopes. , 2008, Chemistry.
[36] R. Brady,et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease , 2008, Proceedings of the National Academy of Sciences.
[37] H. Uludaǧ,et al. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. , 2007, Biomacromolecules.
[38] H. Junginger,et al. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[39] J. Shayman,et al. An in vitro model of Fabry disease. , 2005, Journal of the American Society of Nephrology : JASN.
[40] W. Mark Saltzman,et al. Targeted for drug delivery , 2005 .
[41] Anthony H. Futerman,et al. The cell biology of lysosomal storage disorders , 2004, Nature Reviews Molecular Cell Biology.
[42] D. Garboczi,et al. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. , 2004, Journal of molecular biology.
[43] W. Sly,et al. Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Desnick,et al. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders , 2002, Nature Reviews Genetics.
[45] S. W. Kim,et al. An angiogenic, endothelial-cell-targeted polymeric gene carrier. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[46] X. Dai,et al. An improved synthesis of a selective αvβ3-integrin antagonist cyclo(-RGDfK-) , 2000 .
[47] J. Brussee,et al. Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride , 1998 .
[48] I. Pastan,et al. alpha-Galactosidase A deficient mice: a model of Fabry disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[49] R. Swerlick,et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. , 1992, The Journal of investigative dermatology.
[50] Thomas J. Raub,et al. Adsorptive endocytosis and membrane recycling by cultured primary bovine brain microvessel endothelial cell monolayers. , 1990, Journal of cell science.
[51] R. Braun,et al. Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. , 1988, Analytical biochemistry.
[52] J. Scheerer,et al. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[53] K. J. Dean,et al. Studies on human liver alpha-galactosidases. I. Purification of alpha-galactosidase A and its enzymatic properties with glycolipid and oligosaccharide substrates. , 1979, The Journal of biological chemistry.
[54] R. Desnick,et al. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. , 1973, The Journal of laboratory and clinical medicine.
[55] J. Kint. Fabry's Disease: Alpha-Galactosidase Deficiency , 1970, Science.
[56] R. Brady,et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. , 1967, The New England journal of medicine.
[57] Eun Seong Lee,et al. Poly(L-aspartic acid) nanogels for lysosome-selective antitumor drug delivery. , 2013, Colloids and surfaces. B, Biointerfaces.
[58] L. Rajendran,et al. Subcellular targeting strategies for drug design and delivery , 2010, Nature Reviews Drug Discovery.
[59] Monty Liong,et al. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. , 2008, ACS nano.
[60] V. Muzykantov,et al. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[61] H. Sakuraba,et al. Urinary excretion of the vitronectin receptor (integrin αVβ3) in patients with Fabry disease , 1999 .